Top

Published in:

01-06-2018 | Original Research

Effect of Strontium Ranelate on the Muscle and Vertebrae of Ovariectomized Rats

Authors: D. Saul, B. Harlas, A. Ahrabi, R. L. Kosinsky, D. B. Hoffmann, M. Wassmann, R. Wigger, K. O. Böker, S. Sehmisch, M. Komrakova

Published in: Calcified Tissue International | Issue 6/2018

Abstract

Osteoporosis is often accompanied by sarcopenia. The effect of strontium ranelate (SR) on muscle tissue has not been investigated sufficiently. In this study, the effect of different SR treatments on muscle was studied. Additionally, the lumbar vertebrae were analyzed. Three-month-old female rats were divided into five groups (n = 12): Group 1: untreated (NON-OVX); Group 2: ovariectomized and left untreated (OVX); Group 3: SR after OVX until the study ended (13 weeks, SR prophylaxis and therapy = pr+th); Group 4: OVX and SR for 8 weeks (SR prophylaxis = pr); Group 5: SR for 5 weeks from the 8 week after OVX (SR therapy = SR th). SR was applied in food (630 mg/kg body weight). The size of muscle fibers, capillary density, metabolic enzymes, and mRNA expression were assessed in soleus, gastrocnemius, and longissimus muscles. The vertebral bodies underwent micro-CT, biomechanical, and ashing analyses. In general, SR did not alter the muscle histological parameters. The changes in fiber size and capillary ratio were related to the body weight. Myostatin mRNA was decreased in Sr pr+th; protein expression was not changed. SR th led to increase in mRNA expression of vascular endothelial growth factor (Vegf-B). In lumbar spine, SR pr+th enhanced biomechanical properties, bone mineral density, trabecular area, density, and thickness and cortical density. The reduced calcium/phosphate ratio in the SR pr+th group indicates the replacement of calcium by strontium ions. SR has no adverse effects on muscle tissue and it shows a favorable time-dependent effect on vertebrae. A functional analysis of muscles could verify these findings.

Available only for authorised users

Satpathy S, Patra A, Ahirwar B (2015) Experimental techniques for screening of antiosteoporotic activity in postmenopausal osteoporosis. J Complement Integr Med 12(4):251–266. https://doi.org/10.1515/jcim-2015-0034 CrossRefPubMed

Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733. https://doi.org/10.1007/s00198-006-0172-4 CrossRef

ROLLAND Y, CZERWINSKI S, van KAN, GA et al (2008) Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 12(7):433–450CrossRef

Bruyère O, Beaudart C, Locquet M et al (2016) Sarcopenia as a public health problem. Eur Geriatric Med 7(3):272–275. https://doi.org/10.1016/j.eurger.2015.12.002 CrossRef

Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57. https://doi.org/10.1007/s00198-012-2074-y CrossRefPubMed

DVO (2014) OSTEOPOROSE bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen: Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V

Reginster JY, Seeman E, Vernejoul MC de et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822. https://doi.org/10.1210/jc.2004-1774 CrossRef

Kanis JA, Johansson H, Oden A et al (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int 22(8):2347–2355. https://doi.org/10.1007/s00198-010-1474-0 CrossRefPubMed

Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468. https://doi.org/10.1056/NEJMoa022436 CrossRef

10.

Reginster JY, Brandi ML, Cannata-Andia J et al (2015) The position of strontium ranelate in today’s management of osteoporosis. Osteoporos Int 26(6):1667–1671. https://doi.org/10.1007/s00198-015-3109-y CrossRefPubMed

11.

Reid IR (2015) Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med 277(6):690–706. https://doi.org/10.1111/joim.12339 CrossRefPubMed

12.

Reginster JY (2014) Cardiac concerns associated with strontium ranelate. Expert Opin Drug Saf 13(9):1209–1213. https://doi.org/10.1517/14740338.2014.939169 CrossRefPubMedPubMedCentral

13.

Maeda SS, Lazaretti-Castro M (2014) An overview on the treatment of postmenopausal osteoporosis. Arq Bras Endocrinol Metabol 58(2):162–171CrossRef

14.

Bakker AD, Zandieh-Doulabi B, Klein-Nulend J (2013) Strontium ranelate affects signaling from mechanically-stimulated osteocytes towards osteoclasts and osteoblasts. Bone 53(1):112–119. https://doi.org/10.1016/j.bone.2012.11.044 CrossRefPubMed

15.

Li YF, Luo E, Feng G et al (2010) Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporos Int 21(11):1889–1897. https://doi.org/10.1007/s00198-009-1140-6 CrossRefPubMed

16.

Ozturan KE, Demir B, Yucel I et al (2011) Effect of strontium ranelate on fracture healing in the osteoporotic rats. J Orthop Res 29(1):138–142. https://doi.org/10.1002/jor.21204 CrossRefPubMed

17.

Ammann P, Shen V, Robin B et al (2004) Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19(12):2012–2020. https://doi.org/10.1359/JBMR.040906 CrossRefPubMed

18.

Komrakova M et al (2015) The impact of strontium ranelate on metaphyseal bone healing in ovariectomized rats. Calcif Tissue Int 97(4):391–401. https://doi.org/10.1007/s00223-015-0019-0 CrossRefPubMed

19.

Komrakova M, Hoffmann DB, Nuehnen V et al (2016) The effect of vibration treatments combined with teriparatide or strontium ranelate on bone healing and muscle in ovariectomized rats. Calcif Tissue Int 99(4):408–422. https://doi.org/10.1007/s00223-016-0156-0 CrossRef

20.

Molinuevo MS, Fernandez JM, Cortizo AM et al (2017) Advanced glycation end products and strontium ranelate promote osteogenic differentiation of vascular smooth muscle cells in vitro: preventive role of vitamin D. Mol Cell Endocrinol 450:94–104. https://doi.org/10.1016/j.mce.2017.04.022 CrossRefPubMed

21.

Servier Laboratories Limited (2016) Protelos: summary of product characteristics (SPC)–(eMC). https://www.medicines.org.uk/emc/medicine/15410. Accessed 24 Nov 2016

22.

Cunha-Henriques S, Costa-Paiva L, Pinto-Neto AM et al (2011) Postmenopausal women with osteoporosis and musculoskeletal status: a comparative cross-sectional study. J Clin Med Res 3(4):168–176. https://doi.org/10.4021/jocmr537w CrossRefPubMedPubMedCentral

23.

Kaji H (2013) Linkage between muscle and bone: common catabolic signals resulting in osteoporosis and sarcopenia. Curr Opin Clin Nutr Metab Care 16(3):272–277. https://doi.org/10.1097/MCO.0b013e32835fe6a5 CrossRefPubMed

24.

Sjoblom S, Suuronen J, Rikkonen T et al (2013) Relationship between postmenopausal osteoporosis and the components of clinical sarcopenia. Maturitas 75(2):175–180. https://doi.org/10.1016/j.maturitas.2013.03.016 CrossRefPubMed

25.

He H, Liu Y, Tian Q et al (2015) Relationship of sarcopenia and body composition with osteoporosis. Osteoporos Int. https://doi.org/10.1007/s00198-015-3241-8 CrossRefPubMedPubMedCentral

26.

Iwasa T, Matsuzaki T, Tungalagsuvd A et al (2014) Effects of ovariectomy on the inflammatory responses of female rats to the central injection of lipopolysaccharide. J Neuroimmunol 277(1–2):50–56. https://doi.org/10.1016/j.jneuroim.2014.09.017 CrossRefPubMed

27.

Habermann B, Kafchitsas K, Olender G et al (2010) Strontium ranelate enhances callus strength more than PTH 1–34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int 86(1):82–89. https://doi.org/10.1007/s00223-009-9317-8 CrossRefPubMed

28.

Saul D, Kling JH, Kosinsky RL et al (2016) Effect of the lipoxygenase inhibitor baicalein on muscles in ovariectomized rats. J Nutr Metab. https://doi.org/10.1155/2016/3703216 CrossRefPubMedPubMedCentral

29.

Komrakova M, Krischek C, Wicke M et al (2011) Influence of intermittent administration of parathyroid hormone on muscle tissue and bone healing in orchiectomized rats or controls. J Endocrinol 209(1):9–19. https://doi.org/10.1530/JOE-10-0353 CrossRefPubMed

30.

Andersen P (1975) Capillary density in skeletal muscle of man. Acta Physiol Scand 95(2):203–205. https://doi.org/10.1111/j.1748-1716.1975.tb10043.x CrossRefPubMed

31.

Komrakova M, Werner C, Wicke M et al (2009) Effect of daidzein, 4-methylbenzylidene camphor or estrogen on gastrocnemius muscle of osteoporotic rats undergoing tibia healing period. J Endocrinol 201(2):253–262. https://doi.org/10.1677/JOE-08-0521 CrossRefPubMed

32.

Horák V (1983) A successive histochemical staining for succinate dehydrogenase and ?: Reversed?-ATPase in a single section for the skeletal muscle fibre typing. Histochemistry 78(4):545–553. https://doi.org/10.1007/BF00496207 CrossRefPubMed

33.

Faloona GR, Srere PA (1969) Escherichia coli citrate synthase: purification and the effect of potassium on some properties. Biochemistry 8(11):4497–4503. https://doi.org/10.1021/bi00839a041 CrossRefPubMed

34.

Hatefi Y, Stiggall DL (1978) [2] Preparation and properties of NADH: Cytochrome c oxidoreductase (complex I–III). In: Fleischer S (ed) Biological oxidations: mitochondrial and microbial systems, vol 53. Academy Press, New York, pp 5–10CrossRef

35.

Spandidos A, Wang X, Wang H et al (2010) PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res 38(Database issue):D792–D799. https://doi.org/10.1093/nar/gkp1005 CrossRefPubMed

36.

Spandidos A, Wang X, Wang H et al (2008) A comprehensive collection of experimentally validated primers for polymerase chain reaction quantitation of murine transcript abundance. BMC Genome 9:633. https://doi.org/10.1186/1471-2164-9-633 CrossRef

37.

Wang X, Seed B (2003) A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 31(24):e154CrossRef

38.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262 CrossRefPubMed

39.

Sehmisch S, Erren M, Rack T et al (2009) Short-term effects of parathyroid hormone on rat lumbar vertebrae. Spine 34(19):2014–2021. https://doi.org/10.1097/BRS.0b013e3181afe846 CrossRefPubMed

40.

Sehmisch S, Erren M, Kolios L et al (2010) Effects of isoflavones equol and genistein on bone quality in a rat osteopenia model. Phytother Res 24(Suppl 2): S168–S174. https://doi.org/10.1002/ptr.3060 CrossRef

41.

Hoffmann DB, Griesel MH, Brockhusen B et al. (2016) Effects of 8-prenylnaringenin and whole-body vibration therapy on a rat model of osteopenia. J Nutr Metab. https://doi.org/10.1155/2016/6893137 CrossRefPubMedPubMedCentral

42.

Parfitt A, Drezner MK, Glorieux FH et al (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2(6):595–610. https://doi.org/10.1002/jbmr.5650020617 CrossRef

43.

Bouxsein ML, Boyd SK, Christiansen BA et al (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468–1486. https://doi.org/10.1002/jbmr.141 CrossRef

44.

Sehmisch S, Komrakova M, Kottwitz L et al (2015) Effects of urocortin on spine? Osteologie 24(2):99–106CrossRef

45.

Komrakova M, Stuermer EK, Sturm A, Schmelz U, Tezval M, Stuermer KM, Sehmisch S (2012) Efficiency of 48 h vs. 24 h Injection of parathyroid hormone for amelioration of osteopenic spine properties in male rats. TOBONEJ 4(1): 20–26. https://doi.org/10.2174/1876525401204010020 CrossRef

46.

Dachverband OeV (2014) Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V.: Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen. http://www.dv-osteologie.org/uploads/Leitlinie%202014/DVO-Leitlinie%20Osteoporose%202014%20Kurzfassung%20und%20Langfassung%20Version%201a%2012%2001%202016.pdf. Accessed 10 Dec 2017

47.

Cortet B (2011) Use of strontium as a treatment method for osteoporosis. Curr Osteoporos Rep 9(1):25–30. https://doi.org/10.1007/s11914-010-0042-z CrossRefPubMed

48.

Iniguez-Ariza NM, Clarke BL (2015) Bone biology, signaling pathways, and therapeutic targets for osteoporosis. Maturitas 82(2):245–255. https://doi.org/10.1016/j.maturitas.2015.07.003 CrossRefPubMed

49.

Abboskhujaeva LS, Ismailov SI, Alikhanova NM (2014) Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis. Drugs R D 14(4):315–324. https://doi.org/10.1007/s40268-014-0069-1 CrossRefPubMedPubMedCentral

50.

Nielsen SP, Slosman D, Sorensen OH et al (1999) Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom 2(4):371–379CrossRef

51.

Reginster JY, Kaufman JM, Goemaere S et al (2012) Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 23(3):1115–1122. https://doi.org/10.1007/s00198-011-1847-z CrossRefPubMed

52.

Hegde V, Jo JE, Andreopoulou P et al (2016) Effect of osteoporosis medications on fracture healing. Osteoporos Int 27(3):861–871. https://doi.org/10.1007/s00198-015-3331-7 CrossRefPubMed

53.

Tarantino U, Celi M, Saturnino L et al (2010) Strontium Ranelate and bone healing: report of two cases. Clin Cases Miner Bone Metab 7(1):65–68PubMedPubMedCentral

54.

Fuchs RK, Allen MR, Condon KW et al (2008) Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19(9):1331–1341. https://doi.org/10.1007/s00198-008-0602-6 CrossRef

55.

Bain SD, Jerome C, Shen V et al (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20(8):1417–1428. https://doi.org/10.1007/s00198-008-0815-8 CrossRefPubMed

56.

Dahl SG, Allain P, Marie PJ et al (2001) Incorporation and distribution of strontium in bone. Bone 28(4):446–453CrossRef

57.

Deeks ED, Dhillon S (2010) Spotlight on strontium ranelate: in postmenopausal osteoporosis. Drugs Aging 27(9):771–773. https://doi.org/10.2165/11206440-000000000-00000 CrossRefPubMed

58.

Body JJ, Bergmann P, Boonen S et al. (2012) Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int (23 Suppl 1): S1–S23. https://doi.org/10.1007/s00198-011-1891-8 CrossRef

59.

EMEA (2005) EPAR: scientific discussion: european medicines agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000560/WC500045522.pdf. Accessed 10 Dec 2017

60.

Tsai W-JA, McCormick KM, Brazeau DA et al (2007) Estrogen effects on skeletal muscle insulin-like growth factor 1 and myostatin in ovariectomized rats. Exp Biol Med 232(10):1314–1325. https://doi.org/10.3181/0704-RM-92 CrossRef

61.

Velloso CP (2008) Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol 154(3):557–568. https://doi.org/10.1038/bjp.2008.153 CrossRefPubMedPubMedCentral

62.

Kirk S, Oldham J, Kambadur R et al (2000) Myostatin regulation during skeletal muscle regeneration. J Cell Physiol 184(3):356–363CrossRef

63.

Roth SM, Walsh S (2004) Myostatin: a therapeutic target for skeletal muscle wasting. Curr Opin Clin Nutr Metab Care 7(3):259–263CrossRef

64.

Jasuja R, LeBrasseur NK (2014) Regenerating skeletal muscle in the face of aging and disease. Am J Phys Med Rehabil 93(11 Suppl 3):S88–S96. https://doi.org/10.1097/PHM.0000000000000118 CrossRefPubMed

65.

Wagner PD (2011) The critical role of VEGF in skeletal muscle angiogenesis and blood flow. Biochem Soc Trans 39(6):1556–1559. https://doi.org/10.1042/BST20110646 CrossRefPubMed

66.

Hoier B, Hellsten Y (2014) Exercise-induced capillary growth in human skeletal muscle and the dynamics of VEGF. Microcirculation 21(4):301–314. https://doi.org/10.1111/micc.12117 CrossRef

67.

Ammann P, Badoud I, Barraud S et al (2007) Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 22(9):1419–1425. https://doi.org/10.1359/jbmr.070607 CrossRefPubMed

68.

Chen B, Li Y, Yang X et al (2013) Comparable effects of alendronate and strontium ranelate on femur in ovariectomized rats. Calcif Tissue Int 93(5):481–486. https://doi.org/10.1007/s00223-013-9765-z CrossRefPubMed

69.

Vegger JB, Bruel A, Sorensen TG et al (2016) Systemic Treatment with strontium ranelate does not influence the healing of femoral mid-shaft defects in rats. Calcif Tissue Int 98(2):206–214. https://doi.org/10.1007/s00223-015-0077-3 CrossRefPubMed

70.

Hoffmann DB, Sehmisch S, Am, Hofmann et al (2017) Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis. J Bone Miner Metab 35(1):31–39. https://doi.org/10.1007/s00774-016-0736-0 CrossRefPubMed

71.

Boyd SK, Szabo E, Ammann P (2011) Increased bone strength is associated with improved bone microarchitecture in intact female rats treated with strontium ranelate: a finite element analysis study. Bone 48(5):1109–1116. https://doi.org/10.1016/j.bone.2011.01.004 CrossRefPubMed

72.

Rizzoli R, Laroche M, Krieg MA et al (2010) Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 30(10):1341–1348. https://doi.org/10.1007/s00296-010-1542-y CrossRefPubMedPubMedCentral

73.

Wu Y, Adeeb SM, Duke MJ et al (2013) Compositional and material properties of rat bone after bisphosphonate and/or strontium ranelate drug treatment. J Pharm Pharm Sci 16(1):52–64CrossRef

74.

Oliveira JP, Querido W, Caldas RJ et al (2012) Strontium is incorporated in different levels into bones and teeth of rats treated with strontium ranelate. Calcif Tissue Int 91(3):186–195. https://doi.org/10.1007/s00223-012-9625-2 CrossRefPubMed

75.

Li C, Paris O, Siegel S et al (2010) Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. J Bone Miner Res 25(5):968–975. https://doi.org/10.1359/jbmr.091038 CrossRef

76.

Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15(3):175–191CrossRef

Title: Effect of Strontium Ranelate on the Muscle and Vertebrae of Ovariectomized Rats
Authors: D. Saul
B. Harlas
A. Ahrabi
R. L. Kosinsky
D. B. Hoffmann
M. Wassmann
R. Wigger
K. O. Böker
S. Sehmisch
M. Komrakova
Publication date: 01-06-2018
Publisher: Springer US
Published in: Calcified Tissue International / Issue 6/2018
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-017-0374-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effect of Strontium Ranelate on the Muscle and Vertebrae of Ovariectomized Rats

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

Bone Geometry, Quality, and Bone Markers in Children with Type 1 Diabetes Mellitus

High Serum Retinol as a Relevant Contributor to Low Bone Mineral Density in Postmenopausal Osteoporotic Women

Analysis of Circulating Mediators of Bone Remodeling in Prader–Willi Syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page